scholarly journals Magnetic Resonance Mammography in the Diagnostics of Intraduсtal Cancer in situ (DCIS)

2021 ◽  
pp. 41-61
Author(s):  
S. V. Serebryakova ◽  
T. A. Shumakova ◽  
O. B. Safronova ◽  
E. A. Yuhno ◽  
A. L. Serebryakov
Keyword(s):  
Carcinoma In Situ ◽  
Breast Tissue ◽  
Ductal Carcinoma ◽  
High Sensitivity ◽  
Type Ii ◽  
Mr Mammography ◽  
Dynamic Contrast Enhancement ◽  
Magnetic Resonance Mammography ◽  
High Degree

The improvement of methods of radiation diagnostics has led to an increase in the frequency of detection of breast cancer in the early stages. According to our study (a retrospective analysis of data from 195 MRM with DKU), the results of studies of women with a histologically verified diagnosis of intra-ductal carcinoma in situ (DCIS). For formations of more than 5 mm in 60 %, we obtained reliable criteria for the malignant process (contrast capture of more than 100 % for type II-III, the presence of feeding arteries). Various contrast zones without / or with the presence of less than 5 mm formation in 10–20 % of in situ carcinomas had a pattern of accumulation similar to benign proliferative changes, a statistically significant criterion was the strengthening of the vasculature on MIP reconstruction around the contrast zone, which in 31 % of cases coincided with the areas of accumulation of atypical microcalcinates detected in mammography (BI-RADS 4). MR mammography with dynamic contrast enhancement, having a high sensitivity in detecting vascularized areas, allows us to assess their nature with a high degree of probability against the background of any types of breast tissue structure.

Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography

2005 ◽  
Vol 15 (7) ◽  
pp. 1353-1360 ◽  
Author(s):  
Keiko Oshida ◽  
Takeshi Nagashima ◽  
Takuya Ueda ◽  
Hiroshi Yagata ◽  
Naoto Tanabe ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Pharmacokinetic Analysis ◽  
Mr Mammography ◽  
Dynamic Mr

Assessment of Surgical Operations for Ductal Carcinoma In Situ of the Breast

1997 ◽  
Vol 13 (3) ◽  
pp. 420-429 ◽  
Author(s):  
Xi Peng Yin ◽  
Xiao Qing Li ◽  
Duncan Neuhauser ◽  
James T. Evans
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Clinical Studies ◽  
Surgical Procedure ◽  
Carcinoma In Situ ◽  
Breast Tissue ◽  
Ductal Carcinoma ◽  
Meta Analysis ◽  
Surgical Operations

AbstractThe choice of surgical procedure for the treatment of ductal carcinoma in situ (DCIS) remains clinically based. A meta-analysis was used to synthesize the results of 24 published clinical studies. Partial breast tissue excision appears to be as efficacious as mastectomy for the treatment of DCIS of the breast.

Diagnosis of ductal carcinoma in situ using contrast-enhanced magnetic resonance mammography compared with conventional mammography

2008 ◽  
Vol 32 (6) ◽  
pp. 438-442 ◽  
Author(s):  
Tibor Vag ◽  
Pascal A.T. Baltzer ◽  
Diane M. Renz ◽  
Stefan O.R. Pfleiderer ◽  
Mieczyslaw Gajda ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Contrast Enhanced ◽  
Magnetic Resonance Mammography ◽  
Conventional Mammography

scholarly journals Is Carboxypeptidase B1 a Prognostic Marker for Ductal Carcinoma In Situ?

Cancers ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1726
Author(s):  
Charu Kothari ◽  
Alisson Clemenceau ◽  
Geneviève Ouellette ◽  
Kaoutar Ennour-Idrissi ◽  
Annick Michaud ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Breast Tissue ◽  
Ductal Carcinoma ◽  
Mrna Level ◽  
Gene Signature ◽  
Low Grade ◽  
Tissue Samples ◽  
Ductal Hyperplasia

Ductal carcinoma in situ (DCIS) is considered a non-obligatory precursor for invasive ductal carcinoma (IDC). Around 70% of women with atypical ductal hyperplasia (ADH) undergo unnecessary surgery due to the difficulty in differentiating ADH from low-grade DCIS. If untreated, 14–60% of DCIS progress to IDC, highlighting the importance of identifying a DCIS gene signature. Human transcriptome data of breast tissue samples representing each step of BC progression were analyzed and high expression of carboxypeptidase B1 (CPB1) expression strongly correlated with DCIS. This was confirmed by quantitative PCR in breast tissue samples and cell lines model. High CPB1 expression correlated with better survival outcome, and mRNA level was highest in DCIS than DCIS adjacent to IDC and IDC. Moreover, loss of CPB1 in a DCIS cell line led to invasive properties associated with activation of HIF1α, FN1, STAT3 and SPP1 and downregulation of SFRP1 and OS9. The expression of CPB1 could predict 90.1% of DCIS in a cohort consisting of DCIS and IDC. We identified CPB1, a biomarker that helps differentiate DCIS from ADH or IDC and in predicting if a DCIS is likely to progress to IDC, thereby helping clinicians in their decisions.

scholarly journals Optical tissue measurements of invasive carcinoma and ductal carcinoma in situ for surgical guidance

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Lisanne L. de Boer ◽  
Esther Kho ◽  
Koen K. Van de Vijver ◽  
Marie-Jeanne T. F. D. Vranken Peeters ◽  
Frederieke van Duijnhoven ◽  
...  
Keyword(s):  
Carcinoma In Situ ◽  
Breast Tissue ◽  
Invasive Carcinoma ◽  
Ductal Carcinoma ◽  
Classification Models ◽  
Malignant Tissue ◽  
Surgical Guidance ◽  
Measurement Location

Abstract Background Although the incidence of positive resection margins in breast-conserving surgery has decreased, both incomplete resection and unnecessary large resections still occur. This is especially the case in the surgical treatment of ductal carcinoma in situ (DCIS). Diffuse reflectance spectroscopy (DRS), an optical technology based on light tissue interactions, can potentially characterize tissue during surgery thereby guiding the surgeon intraoperatively. DRS has shown to be able to discriminate pure healthy breast tissue from pure invasive carcinoma (IC) but limited research has been done on (1) the actual optical characteristics of DCIS and (2) the ability of DRS to characterize measurements that are a mixture of tissue types. Methods In this study, DRS spectra were acquired from 107 breast specimens from 107 patients with proven IC and/or DCIS (1488 measurement locations). With a generalized estimating equation model, the differences between the DRS spectra of locations with DCIS and IC and only healthy tissue were compared to see if there were significant differences between these spectra. Subsequently, different classification models were developed to be able to predict if the DRS spectrum of a measurement location represented a measurement location with “healthy” or “malignant” tissue. In the development and testing of the models, different definitions for “healthy” and “malignant” were used. This allowed varying the level of homogeneity in the train and test data. Results It was found that the optical characteristics of IC and DCIS were similar. Regarding the classification of tissue with a mixture of tissue types, it was found that using mixed measurement locations in the development of the classification models did not tremendously improve the accuracy of the classification of other measurement locations with a mixture of tissue types. The evaluated classification models were able to classify measurement locations with > 5% malignant cells with a Matthews correlation coefficient of 0.41 or 0.40. Some models showed better sensitivity whereas others had better specificity. Conclusion The results suggest that DRS has the potential to detect malignant tissue, including DCIS, in healthy breast tissue and could thus be helpful for surgical guidance.

scholarly journals P-cadherin and CD10 Expression to Distinguish between Ductal Carcinoma in Situ and Invasive Ductal Carcinoma of the Breast

2019 ◽  
Author(s):  
Kanet Kanjanapradit ◽  
Sittipong Wangsawibul
Keyword(s):  
Invasive Ductal Carcinoma ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
High Sensitivity ◽  
Myoepithelial Cells ◽  
Luminal Cell ◽  
Cd10 Expression ◽  
Almost All

Objective: To use placental cadherin (P-cadherin) and cluster of differentiation 10 (CD10) immunohisto chemical staining, to separate ductal carcinoma in situ (DCIS) from invasive ductal carcinoma (IDC).Material and Methods: DCIS (n=48), equivocal (n=18), and IDC grade 1 (n=17) cases were evaluated by using immunohisto chemical staining, with P-cadherin and CD10 for identifying the myoepithelial cells.Results: P-cadherin is positive in myoepithelial cells in almost all cases of DCIS (79.0%), and equivocal groups (61.0%). CD10 also shows a positive result in most cases of DCIS (98.0%) along with equivocal groups (72.0%). Both, P-cadherin and CD10 are negative in all cases of IDC grade 1. P-cadherin shows a high percentage of positivity in luminal cell in DCIS (83.0%), equivocal group (100.0%) and IDC grade 1 (88.0%). CD10 shows a low positive in the luminal cell of most cases of DCIS (13.0%), equivocal group (6.0%) and IDC grade 1 (0.0%). CD10 is positive in myofibroblastic cells in approximately 30.0% of all cases, but P-cadherin shows all negative staining.Conclusion: P-cadherin and CD10 show high sensitivity for detecting the myoepithelial cells, but P-cadherin has a lower specificity, due to it having more luminal cells expression. Therefore, P-cadherin may be helpful for diagnosis in some cases that have a high expression of CD10 in myofibroblastic cells.

Pharmacokinetic analysis of ductal carcinoma in situ of the breast using dynamic MR mammography

2006 ◽  
Vol 30 (1) ◽  
pp. 71
Author(s):  
K. Oshida ◽  
T. Nagashima ◽  
T. Ueda ◽  
H. Yagata ◽  
N. Tanabe ◽  
...  
Keyword(s):  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Pharmacokinetic Analysis ◽  
Mr Mammography ◽  
Dynamic Mr
Sign in / Sign up

Export Citation Format

Share Document